1 |
Grcman, M., Vrecer, F., and Meden, A., Some physico-chemical properties of Doxazosin mesylate polymorphic forms and its amorphous state. J. Therm. Anal. Cal., 68, 373-387 (2002)
DOI
ScienceOn
|
2 |
Sun, C. and Grant, D. J. W., Influence of crystal structure on the tableting properties of sulfamerazine polymorphs. Pharm. Res., 18, 274-280 (2001)
DOI
ScienceOn
|
3 |
Gruenenberg, A., Polymorphie und thermische Analyse pharmazeutischer Wirkstoffe. Pharmazie in unserer Zeit, 26, 224-231 (1997)
DOI
PUBMED
ScienceOn
|
4 |
Giron, D., Thermal analysis and calorimetric methods in the characterization of polymorphs and solvates. Thermochim. Acta, 248, 1-59 (1995)
DOI
ScienceOn
|
5 |
Yoshinari, T., Forbes, R. T., York, P., and Kawashima, Y., The improved compaction properties of mannitol after a moistureinduced polymorphic transition. Int. J. Pharm., 258, 121-131 (2003)
DOI
PUBMED
ScienceOn
|
6 |
Borka, L., Reviews on crystal polymorphism of substances in the European Pharmacopoeia. Pharm. Acta Helv., 66, 16-22 (1991)
|
7 |
Sohn, Y. T., Effect of polymorphism on bioavailability of amoxicillin. Yakhak Hoeji, 39, 438-443 (1995)
|
8 |
Haleblian, J., Characterization of habits and crystalline modification of solids and their pharmaceutical applications. J. Pharm. Sci., 64, 1269-1288 (1975)
DOI
PUBMED
|
9 |
Kuhnert-Brandstaetter, M., Polymorphie von Arzneistoffen und ihre Bedeutung in der pharmazeutischen Technologie. Informationsdienst A.P.V., 19, 73-90 (1973)
|
10 |
Sohn, Y. T. and Kim, S. Y., Effect of crystal form on in vivo topical anti-inflammatory activity of corticosteroids. Arch. Pharm. Res., 25, 556-559 (2002)
DOI
ScienceOn
|
11 |
Haleblian, J. and McCrowne, W., Pharmaceutical applications of polymorphism. J. Pharm. Sci., 58, 911-929 (1969)
DOI
PUBMED
|
12 |
Giridhar, T., Reddy, R. B.. and Ramesh, C., Methods for the preparation of polymorphs of doxazosin mesylate. US 6,399,775 B1 (2002)
|